Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel
NASDAQ:HSCS

HeartSciences 12/15/2025 Earnings Report

HeartSciences logo
$1.91 +0.02 (+1.06%)
Closing price 04:00 PM Eastern
Extended Trading
$1.87 -0.04 (-1.94%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HeartSciences EPS Results

Actual EPS
-$0.85
Consensus EPS
-$0.90
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

HeartSciences Revenue Results

Actual Revenue
$2.42 million
Expected Revenue
$0.00 million
Beat/Miss
Beat by +$2.42 million
YoY Revenue Growth
N/A

HeartSciences Announcement Details

Quarter
Date
12/15/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HeartSciences' next earnings date is estimated for Thursday, July 23, 2026, based on past reporting schedules.

Conference Call Resources

HeartSciences Earnings Headlines

HeartSciences Stockholders Approve Director Election and Equity Plan
May 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-stockholders-approve-director-election-and-equity-plan?utm_source=marketbeat.com&utm_medium=referral
HeartSciences Inc.: HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights
May 5, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-05/68399060-heartsciences-inc-heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights-399.htm
Millionaire warns: Move your money now
Larry Benedict, the hedge fund trader who generated $274 million in profits for clients and beat the S&P 500 by 18 times in 2025, says Trump's installation of a new Federal Reserve chair is triggering the most significant shift in U.S. markets in nearly 20 years. Benedict's track record around Fed moves is hard to ignore - 62% from a single position after 2020 rate cuts, 117% in under a month when rate hikes were signaled in 2022, and an 89% gain in 17 days following a Jackson Hole speech. He has already identified the one ticker he believes will be at the center of the coming money flows, and he's sharing it free.tc pixel
May 14 at 1:00 AM  |  Brownstone Research (Ad)
HeartSciences Signs First SaaS Revenues Agreement following full launch of MyoVista Insights™
May 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3287733/0/en/heartsciences-signs-first-saas-revenues-agreement-following-full-launch-of-myovista-insights.html
HeartSciences Reminds Its Shareholders to Submit Their Vote at the Upcoming April 30, 2026, Annual Shareholders Meeting
April 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/14/3273913/0/en/heartsciences-reminds-its-shareholders-to-submit-their-vote-at-the-upcoming-april-30-2026-annual-shareholders-meeting.html
HeartSciences COO and Longtime Board Member Passes Away
April 3, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/heartsciences-coo-and-longtime-board-member-passes-away?utm_source=marketbeat.com&utm_medium=referral
See More HeartSciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email.

About HeartSciences

HeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows. The technology has received regulatory clearance in key markets including the United States and European Union, and the company continues to forge distribution partnerships and develop direct sales channels to broaden its reach among cardiology practices, hospitals and primary care providers. Concurrently, HeartSciences is advancing its research efforts to explore additional clinical applications and refine its diagnostic algorithms.

Headquartered in Bothell, Washington, HeartSciences maintains research and development operations in the United States and collaborates with academic and clinical institutions to validate and expand its platform. As a publicly traded company on the NASDAQ exchange, HeartSciences is led by an executive team and governed by a board of directors committed to driving innovation in non‐invasive cardiovascular diagnostics. Through ongoing product development and strategic partnerships, the company aims to enhance patient outcomes and support clinicians with robust, data‐driven diagnostic tools.

View HeartSciences Profile
Earnings Tools